Table 2.
Survivors (n=59) | Non-survivors (n=10) | t | P | |
---|---|---|---|---|
WBC | 4.98±1.42 | 4.32±2.23 | 0.902 | 0.388 |
N | 3.25±1.15 | 2.86±1.50 | 0.952 | 0.344 |
LY% | 26.86±7.85 | 25.00±9.85 | 0.665 | 0.509 |
LY | 1.26±0.44 | 1.02±0.85 | 0.857 | 0.412 |
RBC | 4.10±0.42 | 4.17±0.63 | −0.426 | 0.672 |
HGB | 125.07±12.63 | 128.15±20.56 | −0.458 | 0.657 |
PLT | 100.28±41.27 | 51.90±21.37 | 3.610 | 0.001 |
AST | 168.73±151.19 | 671.87±665.9 | −2.379 | 0.041 |
LDH | 565.67±209.93 | 1791.61±1654.27 | −2.340 | 0.044 |
CK-MB | 29.66±13.17 | 86.81±60.42 | −2.979 | 0.015 |
CRP | 11.04±14.28 | 24.12±25.56 | −1.498 | 0.169 |
PCT | 0.25±0.32 | 0.75±0.57 | −2.554 | 0.031 |
K | 3.82±0.38 | 4.10±0.29 | −2.183 | 0.033 |
Na | 137.11±3.37 | 133.33±4.30 | 3.147 | 0.002 |
Cl | 98.53±3.17 | 95.64±5.26 | 1.689 | 0.122 |
PT | 10.88±1.52 | 12.03±3.07 | −1.161 | 0.273 |
APTT | 45.82±14.70 | 53.73±13.29 | −1.587 | 0.117 |
TT | 17.23±2.44 | 18.70±3.84 | −1.593 | 0.116 |
ALT | 92.45±62.76 | 166.36±159.82 | −1.444 | 0.181 |
TBIL | 15.08±5.24 | 16.98±8.78 | −0.955 | 0.343 |
DBIL | 6.38±3.37 | 9.73±6.28 | −1.649 | 0.130 |
GLO | 31.15±4.37 | 30.19±6.62 | 0.595 | 0.554 |
GGT | 86.2±112.63 | 95.46±85.95 | −0.247 | 0.805 |
ALP | 92.07±51.70 | 115.93±56.48 | −1.332 | 0.187 |
BNP | 1880.93±3051.83 | 8675.91±10560.09 | −1.432 | 0.224 |
WBC – white blood cells; N – neutrophils; LY% – lymphocyte percentage; LY – lymphocytes; RBC – red blood cells; HGB – hemoglobin; PLT – platelets; AST – aspartate aminotransferase; LDH – lactate dehydrogenase; CK-MB – creatine kinase-MB; CRP – C-reactive protein; PCT – procalcitonin; K – potassium; Na – sodium; Cl – chloride; PT – prothrombin time; APTT – activated partial thromboplastin time; TT – thrombin time; ALT – alanine aminotransferase; TBIL – total bilirubin; DBIL – direct bilirubin; GLO – globulin; GGT – gamma-glutamyl transferase; ALP – alkaline phosphatase; BNP – brain natriuretic peptide.